Moderna is now overvalued after cancer vaccine-led stock surge, Rothschild & Co. says
The research firm downgraded the biotechnology stock to sell from neutral.
Overview
The research firm downgraded the biotechnology stock to sell from neutral.
Source
Originally published at www.cnbc.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.